142 related articles for article (PubMed ID: 14695147)
1. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer.
Kuefer R; Hofer MD; Gschwend JE; Pienta KJ; Sanda MG; Chinnaiyan AM; Rubin MA; Day ML
Clin Cancer Res; 2003 Dec; 9(17):6447-52. PubMed ID: 14695147
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
3. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.
Davies G; Jiang WG; Mason MD
Clin Cancer Res; 2001 Oct; 7(10):3289-97. PubMed ID: 11595727
[TBL] [Abstract][Full Text] [Related]
4. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Umbas R; Schalken JA; Aalders TW; Carter BS; Karthaus HF; Schaafsma HE; Debruyne FM; Isaacs WB
Cancer Res; 1992 Sep; 52(18):5104-9. PubMed ID: 1516067
[TBL] [Abstract][Full Text] [Related]
5. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy.
Kuniyasu H; Ukai R; Johnston D; Troncoso P; Fidler IJ; Pettaway CA
Clin Cancer Res; 2003 Jun; 9(6):2185-94. PubMed ID: 12796385
[TBL] [Abstract][Full Text] [Related]
6. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate.
Rashid MG; Sanda MG; Vallorosi CJ; Rios-Doria J; Rubin MA; Day ML
Cancer Res; 2001 Jan; 61(2):489-92. PubMed ID: 11212238
[TBL] [Abstract][Full Text] [Related]
7. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone.
Saha B; Kaur P; Tsao-Wei D; Naritoku WY; Groshen S; Datar RH; Jones LW; Imam SA
Prostate; 2008 Nov; 68(15):1681-8. PubMed ID: 18712716
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
Saha B; Arase A; Imam SS; Tsao-Wei D; Naritoku WY; Groshen S; Jones LW; Imam SA
Prostate; 2008 Jan; 68(1):78-84. PubMed ID: 18008331
[TBL] [Abstract][Full Text] [Related]
9. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
Song Y; Oda Y; Hori M; Kuroiwa K; Ono M; Hosoi F; Basaki Y; Tokunaga S; Kuwano M; Naito S; Tsuneyoshi M
Hum Pathol; 2010 Feb; 41(2):214-22. PubMed ID: 19800102
[TBL] [Abstract][Full Text] [Related]
10. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of metastasis-associated proteins in prostate cancer cell lines with different metastatic potentials].
Luo Y; He DL; Ning L; Zhu GD; Shen SL
Zhonghua Nan Ke Xue; 2006 Mar; 12(3):230-3. PubMed ID: 16597039
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer.
Jaggi M; Rao PS; Smith DJ; Wheelock MJ; Johnson KR; Hemstreet GP; Balaji KC
Cancer Res; 2005 Jan; 65(2):483-92. PubMed ID: 15695390
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
Jaggi M; Johansson SL; Baker JJ; Smith LM; Galich A; Balaji KC
Urol Oncol; 2005; 23(6):402-6. PubMed ID: 16301117
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
17. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
18. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
19. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.
Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M
Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864
[TBL] [Abstract][Full Text] [Related]
20. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]